As the U.S. economy continues to feel the ripple effect of the coronavirus pandemic and more Americans lose their jobs, will patients be able to afford their medications?

It’s a question that matters across therapeutic areas and one that will impact manufacturers’ commercialization strategies, especially as it relates to patient and provider support. 

Watch a panel of experts from Lash Group and Xcenda as they offer insights on:

• How the COVID-19 pandemic will impact insurance coverage
• The resulting affordability challenges patients will face
• How manufacturers can adapt their patient assistance programs to ensure access to important therapies